Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

The FDA has granted full approval to Bristol Myers Squibb’s (BMS) dual immunotherapy regimen of Opdivo (nivolumab) plus Yervoy (ipilimumab) for adults with unresectable or metastatic hepatocellular ...

Radiomics Group, led by Raquel Perez-Lopez, have developed SALSA (System for Automatic Liver tumor Segmentation And detection ...

Berlin: Bayer has announced the initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational ...

Hepatocellular carcinoma (HCC) is a common malignant tumor and the third leading cause of cancer-related mortality. The lack ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC).

Gastrointestinal cancers often develop silently but knowing risk factors and warning signs can lead to earlier detection and ...